Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 28, 2025, details a material definitive agreement entered into by Pasithea Therapeutics Corp. The Company, an emerging growth company incorporated in Delaware, announced a best efforts public offering of common stock and pre-funded warrants. The offering closed on December 1, 2025.
Key Financial Metrics and Capital Raise
- Gross Proceeds: Approximately $60.0 million.
- Net Proceeds: Approximately $54.9 million (after placement agent fees and estimated offering expenses).
- Securities Issued: 14,846,665 shares of Common Stock and 65,153,335 Pre-Funded Warrants.
- Offering Prices: $0.75 per Common Stock share; $0.749 per Pre-Funded Warrant.
- Placement Agent Fees: 7.0% of gross proceeds paid in cash to H.C. Wainwright & Co., LLC, plus warrants to purchase 4,000,000 shares at $0.9375 per share.
- Insider Participation: Company insiders (including CEO and CFO) purchased 400,000 shares for approximately $300,000.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement to raise capital for general corporate purposes, including research, clinical trials, and potential acquisitions. Key terms include:
- Pre-Funded Warrants: Immediately exercisable at $0.001 per share, subject to beneficial ownership limitations of 4.99% (or up to 9.99% with notice).
- Lock-Up Provisions: The Company agreed not to issue additional equity or convertible securities for 90 days post-closing, with a one-year restriction on Variable Rate Transactions.
- Use of Proceeds: Funds will support ongoing research, pre-clinical studies, clinical trials, technology development, and working capital.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance its pipeline of biological and pharmaceutical technologies and to pursue strategic licensing or acquisition opportunities. The filing notes that the Placement Agent Warrants were issued pursuant to Section 4(a)(2) exemptions and are not registered under the Securities Act. No specific financial guidance or forward-looking revenue projections were provided in this filing.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $54.9 million.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Confirm the impact of the 65,153,335 Pre-Funded Warrants on fully diluted share count and potential dilution.
- Monitor the 90-day lock-up period expiration for potential future equity issuances.
- Check subsequent filings for updates on the allocation of funds to specific clinical trials or acquisitions.